Mathias Francois
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mathias Francois has a total of 586 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin M. Hogan
Peter MacCallum Cancer Centre
18 shared publications - Peter Koopman
Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia
15 shared publications Cathy Pichol-Thievend
Institute for Molecular Bioscience, the University of Queensland, St Lucia, 4072 QLD, Australia; Tumor Microenvironment Laboratory, Institute Curie Research Center, Paris Saclay University, PSL Research University, Inserm U1021, CNRS, UMR3347 Orsay, France
12 shared publications- Emma Sierecki
Department of Molecular Medicine and European Molecular Biology Laboratory Australia Node in Single Molecule Science, School of Biomedical Sciences, University of New South Wales
10 shared publications Mehdi Moustaqil
10 shared publicationsEmmanuelle Lesieur
9 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Nature Chemical Biology
- p. 1-13
DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells
Histone lysine demethylase 4 (KDM4) enzymes are frequently overexpressed in cancer and are considered to be promising therapeutic targets. QC6352, which is widely used as a best-in-class KDM4 chemical probe, shows potent antitumor activity across cancer models. Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition. Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity. Uridine supplementation and expression of an inhibitor-resistant DHODH mutant fully abrogate growth inhibition, whereas the orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352. These findings establish QC6352 and zavondemstat as dual KDM4–DHODH inhibitors and identify DHODH inhibition as the dominant driver of their antiglioblastoma efficacy, as well as demonstrating the need for orthogonal chemical probes to accurately define drug mechanisms in cells.
- 6 October 2026
- Published by Springer Nature in Nature Chemical Biology
- p. 1-13
Open AccessDHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells
Histone lysine demethylase 4 (KDM4) enzymes are frequently overexpressed in cancer and are considered to be promising therapeutic targets. QC6352, which is widely used as a best-in-class KDM4 chemical probe, shows potent antitumor activity across cancer models. Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition. Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity. Uridine supplementation and expression of an inhibitor-resistant DHODH mutant fully abrogate growth inhibition, whereas the orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352. These findings establish QC6352 and zavondemstat as dual KDM4–DHODH inhibitors and identify DHODH inhibition as the dominant driver of their antiglioblastoma efficacy, as well as demonstrating the need for orthogonal chemical probes to accurately define drug mechanisms in cells.
- Open Access
Piezo1 couples fluid shear stress to adaptive genome dynamics by integrating cytoplasmic-nuclear mechanotransduction
Fluid shear stress (FSS) regulates endothelial morphology and function through flow-responsive gene expression programs. Yet, how mechanical forces are transmitted across cytoplasmic and nuclear compartments to regulate genome adaptive response remains unclear. Here, we show that FSS induces rapid nuclear remodeling characterized by nuclear compaction and apical nuclear indentations. These changes are driven by reorganization of perinuclear actin and microtubule cytoskeleton into apical linear cytoskeletal cables that constrain the nuclear surface. Concurrently, the mechanosensitive ion channel Piezo1 redistributes from the plasma membrane to these perinuclear deformations. Quantitative molecular imaging under flow reveals a transient adaptive cell state characterized by chromatin reorganization and epigenetic remodeling, accompanied by altered mobility of the flow-responsive transcription factor KLF2. Pharmacological inhibition of Piezo1 abolishes FSS-induced nuclear deformation and uncouples chromatin reorganization from KLF2 dynamic changes. Together, these findings reveal that endothelial mechanotransduction exploits physical principles of nuclear organization to regulate transcription factor behavior and adaptive genome responses across biological scales.
Open AccessPiezo1 couples fluid shear stress to adaptive genome dynamics by integrating cytoplasmic-nuclear mechanotransduction
Fluid shear stress (FSS) regulates endothelial morphology and function through flow-responsive gene expression programs. Yet, how mechanical forces are transmitted across cytoplasmic and nuclear compartments to regulate genome adaptive response remains unclear. Here, we show that FSS induces rapid nuclear remodeling characterized by nuclear compaction and apical nuclear indentations. These changes are driven by reorganization of perinuclear actin and microtubule cytoskeleton into apical linear cytoskeletal cables that constrain the nuclear surface. Concurrently, the mechanosensitive ion channel Piezo1 redistributes from the plasma membrane to these perinuclear deformations. Quantitative molecular imaging under flow reveals a transient adaptive cell state characterized by chromatin reorganization and epigenetic remodeling, accompanied by altered mobility of the flow-responsive transcription factor KLF2. Pharmacological inhibition of Piezo1 abolishes FSS-induced nuclear deformation and uncouples chromatin reorganization from KLF2 dynamic changes. Together, these findings reveal that endothelial mechanotransduction exploits physical principles of nuclear organization to regulate transcription factor behavior and adaptive genome responses across biological scales.
- Open Access
- 18 August 2025
- Published by Springer Nature in Research Square
Oncogenic virus hijacks SOX18 pioneer function to enhance viral persistence
Kaposi’s sarcoma herpesvirus (KSHV) establishes lifelong oncogenic infection in lymphatic endothelial cells (LECs) by ensuring episomal maintenance of its genome via the viral protein LANA. Efficient viral genome maintenance typically involves host DNA replication and episome tethering, but the extent of cell-type-specific regulation remains unclear. Here, we identify that KSHV hijacks the pioneering function of the endothelial-specific transcription factor SOX18 to facilitate persistence of viral episomes. Upon infection, LANA co-opts SOX18 to recruit the SWI/SNF chromatin-remodeling complex via its ATPase subunit BRG1, enhancing chromatin accessibility and enabling efficient viral genome persistence. Disruption of SOX18 or BRG1—genetically or pharmacologically—leads to reduced episome load and attenuated hallmarks of virus infection. This work highlights how viruses can harness lineage-specific transcriptional regulators to establish persistent nuclear retention of their episome into the host genome.
- 18 August 2025
- Published by Springer Nature in Research Square
Open AccessOncogenic virus hijacks SOX18 pioneer function to enhance viral persistence
Kaposi’s sarcoma herpesvirus (KSHV) establishes lifelong oncogenic infection in lymphatic endothelial cells (LECs) by ensuring episomal maintenance of its genome via the viral protein LANA. Efficient viral genome maintenance typically involves host DNA replication and episome tethering, but the extent of cell-type-specific regulation remains unclear. Here, we identify that KSHV hijacks the pioneering function of the endothelial-specific transcription factor SOX18 to facilitate persistence of viral episomes. Upon infection, LANA co-opts SOX18 to recruit the SWI/SNF chromatin-remodeling complex via its ATPase subunit BRG1, enhancing chromatin accessibility and enabling efficient viral genome persistence. Disruption of SOX18 or BRG1—genetically or pharmacologically—leads to reduced episome load and attenuated hallmarks of virus infection. This work highlights how viruses can harness lineage-specific transcriptional regulators to establish persistent nuclear retention of their episome into the host genome.
- Open Access
Oncogenic virus hijacks SOX18 pioneer function to enhance viral persistence
Kaposi’s sarcoma herpesvirus (KSHV) establishes lifelong oncogenic infection in lymphatic endothelial cells (LECs) by ensuring episomal maintenance of its genome via the viral protein LANA. Efficient viral genome maintenance typically involves host DNA replication and episome tethering, but the extent of cell-type-specific regulation remains unclear. Here, we identify that KSHV hijacks the pioneering function of the endothelial-specific transcription factor SOX18 to facilitate persistence of viral episomes. Upon infection, LANA co-opts SOX18 to recruit the SWI/SNF chromatin-remodeling complex via its ATPase subunit BRG1, enhancing chromatin accessibility and enabling efficient viral genome persistence. Disruption of SOX18 or BRG1—genetically or pharmacologically—leads to reduced episome load and attenuated hallmarks of virus infection. This work highlights how viruses can harness lineage-specific transcriptional regulators to establish persistent nuclear retention of their episome into the host genome.
Open AccessOncogenic virus hijacks SOX18 pioneer function to enhance viral persistence
Kaposi’s sarcoma herpesvirus (KSHV) establishes lifelong oncogenic infection in lymphatic endothelial cells (LECs) by ensuring episomal maintenance of its genome via the viral protein LANA. Efficient viral genome maintenance typically involves host DNA replication and episome tethering, but the extent of cell-type-specific regulation remains unclear. Here, we identify that KSHV hijacks the pioneering function of the endothelial-specific transcription factor SOX18 to facilitate persistence of viral episomes. Upon infection, LANA co-opts SOX18 to recruit the SWI/SNF chromatin-remodeling complex via its ATPase subunit BRG1, enhancing chromatin accessibility and enabling efficient viral genome persistence. Disruption of SOX18 or BRG1—genetically or pharmacologically—leads to reduced episome load and attenuated hallmarks of virus infection. This work highlights how viruses can harness lineage-specific transcriptional regulators to establish persistent nuclear retention of their episome into the host genome.
- Open Access
NKX2-5 congenital heart disease mutations show diverse loss and gain of epigenomic, biochemical and chromatin search functions underpinning pathogenicity
Congenital heart defects (CHD) occur in ∼1% of live births, with inherited and acquired mutations and environmental factors contributing to causation. However, network perturbations in CHD remain poorly understood. We report an integrated functional-epigenomics approach to CHD, focusing on the cardiac homeodomain (HD) transcription factor NKX2-5, mutations which cause diverse heart structural and conduction defects. We selected twelve NKX2-5 CHD variants affecting different residue classes - homeodomain DNA base-contacting, backbone-contacting and helix-stabilizing, and those affecting other conserved protein:protein interaction (PPI) domains. In HL-1 cardiomyocytes, we profiled genome-wide DNA targets of NKX2-5 wild type (WT) and variants, their DNA binding affinity and specificity, PPI with known NKX2-5 cofactors and chromatin search dynamics. Variants showed diverse yet class-specific behaviours. All variants failed to bind many WT targets but retained binding to a subset of core cardiomyocyte-related targets, and bound hundreds of unique “off-targets” via changes to DNA binding site specificity, homodimerization, cofactor interactions and chromatin search functions. Our data suggest that complex residue-by-residue scale epigenomic, biochemical and chromatin search defects involving both loss-and gain-of-function contribute to CHD. These findings may inform precision molecular therapeutic approaches in patients with CHD.
Open AccessNKX2-5 congenital heart disease mutations show diverse loss and gain of epigenomic, biochemical and chromatin search functions underpinning pathogenicity
Congenital heart defects (CHD) occur in ∼1% of live births, with inherited and acquired mutations and environmental factors contributing to causation. However, network perturbations in CHD remain poorly understood. We report an integrated functional-epigenomics approach to CHD, focusing on the cardiac homeodomain (HD) transcription factor NKX2-5, mutations which cause diverse heart structural and conduction defects. We selected twelve NKX2-5 CHD variants affecting different residue classes - homeodomain DNA base-contacting, backbone-contacting and helix-stabilizing, and those affecting other conserved protein:protein interaction (PPI) domains. In HL-1 cardiomyocytes, we profiled genome-wide DNA targets of NKX2-5 wild type (WT) and variants, their DNA binding affinity and specificity, PPI with known NKX2-5 cofactors and chromatin search dynamics. Variants showed diverse yet class-specific behaviours. All variants failed to bind many WT targets but retained binding to a subset of core cardiomyocyte-related targets, and bound hundreds of unique “off-targets” via changes to DNA binding site specificity, homodimerization, cofactor interactions and chromatin search functions. Our data suggest that complex residue-by-residue scale epigenomic, biochemical and chromatin search defects involving both loss-and gain-of-function contribute to CHD. These findings may inform precision molecular therapeutic approaches in patients with CHD.
- Open Access
Biophysical dissection of SOX18/NR2F2 transcriptional antagonism reveals mechanisms of venous differentiation and drug action in vascular malformation
Translating genomic discoveries into therapies for rare genetic disorders remains a significant challenge, particularly for variants of unknown significance (VUS) where molecular mechanisms are unclear. This is particularly relevant in vascular malformations, where venous differentiation remains poorly understood, and the role of transcription factors in specifying venous identity is only beginning to be elucidated. Here, we combine live-cell single-molecule imaging with genomics-based approaches to uncover a biophysical mechanism of transcription factor antagonism that underpins venous identity. We show that SOX18 and NR2F2 antagonistically co-regulate venous differentiation through dynamic feedback between their nuclear populations. This interaction is disrupted in vascular malformation syndrome caused by a de novo heterozygous NR2F2 mutation, presenting with aberrant vascular integrity and bleeding. Treatment with an FDA-approved drug—known to inhibit SOX18—led to marked clinical improvement in the proband. To dissect the molecular mechanism underlying this mutation and the drug response, we used human embryonic stem cells (hESCs) engineered to carry the proband’s NR2F2 variant. These cells exhibited impaired hESC to venous differentiation with no effect on artery EC differentiation. In silico modelling and live-cell molecular imaging revealed that the NR2F2 variant is hyper-mobile, fails to form homodimers, and cannot recruit SOX18, thereby disrupting a critical transcriptional antagonism that underpins venous endothelial identity. We demonstrate that targeted pharmacological inhibition of SOX18 restores this regulatory balance in hESC-derived venous endothelial cells, rescuing both gene expression and NR2F2 binding dynamics at the single-molecule level. Together, this study uncovers a biophysical mechanism of transcription factor antagonism that governs venous differentiation and offers a framework for developing targeted therapies for rare vascular malformations.
Open AccessBiophysical dissection of SOX18/NR2F2 transcriptional antagonism reveals mechanisms of venous differentiation and drug action in vascular malformation
Translating genomic discoveries into therapies for rare genetic disorders remains a significant challenge, particularly for variants of unknown significance (VUS) where molecular mechanisms are unclear. This is particularly relevant in vascular malformations, where venous differentiation remains poorly understood, and the role of transcription factors in specifying venous identity is only beginning to be elucidated. Here, we combine live-cell single-molecule imaging with genomics-based approaches to uncover a biophysical mechanism of transcription factor antagonism that underpins venous identity. We show that SOX18 and NR2F2 antagonistically co-regulate venous differentiation through dynamic feedback between their nuclear populations. This interaction is disrupted in vascular malformation syndrome caused by a de novo heterozygous NR2F2 mutation, presenting with aberrant vascular integrity and bleeding. Treatment with an FDA-approved drug—known to inhibit SOX18—led to marked clinical improvement in the proband. To dissect the molecular mechanism underlying this mutation and the drug response, we used human embryonic stem cells (hESCs) engineered to carry the proband’s NR2F2 variant. These cells exhibited impaired hESC to venous differentiation with no effect on artery EC differentiation. In silico modelling and live-cell molecular imaging revealed that the NR2F2 variant is hyper-mobile, fails to form homodimers, and cannot recruit SOX18, thereby disrupting a critical transcriptional antagonism that underpins venous endothelial identity. We demonstrate that targeted pharmacological inhibition of SOX18 restores this regulatory balance in hESC-derived venous endothelial cells, rescuing both gene expression and NR2F2 binding dynamics at the single-molecule level. Together, this study uncovers a biophysical mechanism of transcription factor antagonism that governs venous differentiation and offers a framework for developing targeted therapies for rare vascular malformations.
- Top Cited PapersOpen Access
- 11 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (7)
An endothelial SOX18–mevalonate pathway axis enables repurposing of statins for infantile hemangioma
Infantile hemangioma (IH) is the most common tumor in children and a paradigm for pathological vasculogenesis, angiogenesis, and regression. Propranolol, the mainstay of treatment, inhibits IH vessel formation via a β-adrenergic receptor-independent off-target effect of its R(+) enantiomer on endothelial SOX18 - a member of the SOX (SRY-related HMG-box) family of transcription factors. Transcriptomic profiling of patient-derived hemangioma stem cells uncovered the mevalonate pathway (MVP) as a target of R(+) propranolol. Loss and gain of function of SOX18 confirmed it is both necessary and sufficient for R(+) propranolol suppression of the MVP, including regulation of sterol regulatory element–binding protein 2 (SREBP2) and the rate-limiting enzyme HMG-CoA reductase (HMGCR). A biological relevance of the endothelial SOX18-MVP axis in IH patient tissue was demonstrated by nuclear colocalization of SOX18 and SREBP2. Functional validation in a preclinical IH xenograft model revealed that statins — competitive inhibitors of HMGCR — efficiently suppress IH vessel formation. We propose an endothelial SOX18-MVP axis as a central regulator of IH pathogenesis and suggest statin repurposing to treat IH. The pleiotropic effects of R(+) propranolol and statins along the SOX18-MVP axis to disable an endothelial cell–specific program may have therapeutic implications for other vascular disease entities involving pathological vasculogenesis and angiogenesis.
- 11 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (7)
Top Cited PapersOpen AccessAn endothelial SOX18–mevalonate pathway axis enables repurposing of statins for infantile hemangioma
Infantile hemangioma (IH) is the most common tumor in children and a paradigm for pathological vasculogenesis, angiogenesis, and regression. Propranolol, the mainstay of treatment, inhibits IH vessel formation via a β-adrenergic receptor-independent off-target effect of its R(+) enantiomer on endothelial SOX18 - a member of the SOX (SRY-related HMG-box) family of transcription factors. Transcriptomic profiling of patient-derived hemangioma stem cells uncovered the mevalonate pathway (MVP) as a target of R(+) propranolol. Loss and gain of function of SOX18 confirmed it is both necessary and sufficient for R(+) propranolol suppression of the MVP, including regulation of sterol regulatory element–binding protein 2 (SREBP2) and the rate-limiting enzyme HMG-CoA reductase (HMGCR). A biological relevance of the endothelial SOX18-MVP axis in IH patient tissue was demonstrated by nuclear colocalization of SOX18 and SREBP2. Functional validation in a preclinical IH xenograft model revealed that statins — competitive inhibitors of HMGCR — efficiently suppress IH vessel formation. We propose an endothelial SOX18-MVP axis as a central regulator of IH pathogenesis and suggest statin repurposing to treat IH. The pleiotropic effects of R(+) propranolol and statins along the SOX18-MVP axis to disable an endothelial cell–specific program may have therapeutic implications for other vascular disease entities involving pathological vasculogenesis and angiogenesis.
- 20 November 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (4) , 757-759
R(+) propranolol decreases lipid accumulation in haemangioma-derived stem cells
Infantile haemangioma (IH), often treated with propranolol, is a benign vascular tumour that undergoes a spontaneous involution to a fibrofatty residuum. We investigated how R(+) propranolol, the nonbeta blocker enantiomer of racaemic propranolol, affects lipid accumulation and adipogenesis in IH. This was motivated by our previous work showing that R(+) propranolol can block blood vessel formation in a preclinical model of IH. Our findings suggest a novel regulatory role for R(+) propranolol in modulating lipid accumulation in haemangioma stem cells. This highlights a novel role for R(+) propranolol in the involuting phase of IH and offers a strategy to reduce fibrofatty residua in IH.
- 20 November 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (4) , 757-759
R(+) propranolol decreases lipid accumulation in haemangioma-derived stem cells
Infantile haemangioma (IH), often treated with propranolol, is a benign vascular tumour that undergoes a spontaneous involution to a fibrofatty residuum. We investigated how R(+) propranolol, the nonbeta blocker enantiomer of racaemic propranolol, affects lipid accumulation and adipogenesis in IH. This was motivated by our previous work showing that R(+) propranolol can block blood vessel formation in a preclinical model of IH. Our findings suggest a novel regulatory role for R(+) propranolol in modulating lipid accumulation in haemangioma stem cells. This highlights a novel role for R(+) propranolol in the involuting phase of IH and offers a strategy to reduce fibrofatty residua in IH.
- Open Access
RNA-mediated SOX2 temporal dynamics govern dual chromatin-engagement modes at Nanog
Stem cell self-renewal relies on finely tuned transcriptional oscillations of pluripotency genes, yet the sequence by which transcription factors (TFs) govern “on” and “off” states remains unclear. Here, we integrate trimodal single-molecule imaging - SOX2 mobility, Nanog locus diffusion, and real-time Nanog mRNA synthesis using the STREAMING-tag reporter - to visualise endogenous regulatory dynamics in living cells. We identify two SOX2 binding modes linked to transcriptional priming and termination and show coordinated temporal activity of SOX2, OCT4, BRD4, and MED22 at the Nanog locus. Live-cell and fixed-cell measurements reveal that local RNA fluctuations modulate SOX2 visiting-frequency rates. During the active elongation, high nascent enhancer and mRNA levels transiently sequester SOX2 through non-specific interactions, reducing its effective repetitive rebinding and limiting interference with elongating polymerase. After transcript release, declining RNA density permits SOX2 re-engagement, with high-visiting frequency with longer residency and increased locus mobility. These dynamics reveal RNA-dependent feedback that alternately buffers and primes transcriptional re-initiation.
Open AccessRNA-mediated SOX2 temporal dynamics govern dual chromatin-engagement modes at Nanog
Stem cell self-renewal relies on finely tuned transcriptional oscillations of pluripotency genes, yet the sequence by which transcription factors (TFs) govern “on” and “off” states remains unclear. Here, we integrate trimodal single-molecule imaging - SOX2 mobility, Nanog locus diffusion, and real-time Nanog mRNA synthesis using the STREAMING-tag reporter - to visualise endogenous regulatory dynamics in living cells. We identify two SOX2 binding modes linked to transcriptional priming and termination and show coordinated temporal activity of SOX2, OCT4, BRD4, and MED22 at the Nanog locus. Live-cell and fixed-cell measurements reveal that local RNA fluctuations modulate SOX2 visiting-frequency rates. During the active elongation, high nascent enhancer and mRNA levels transiently sequester SOX2 through non-specific interactions, reducing its effective repetitive rebinding and limiting interference with elongating polymerase. After transcript release, declining RNA density permits SOX2 re-engagement, with high-visiting frequency with longer residency and increased locus mobility. These dynamics reveal RNA-dependent feedback that alternately buffers and primes transcriptional re-initiation.
- Open Access
R(+) Propranolol decreases lipid accumulation in hemangioma-derived stem cells
Background Infantile hemangioma (IH) is a benign vascular tumor that undergoes an initial rapid growth phase followed by spontaneous involution. A fibrofatty residuum remains in many tumors and often necessitates resection. We recently discovered that R(+) propranolol, the non-β blocker enantiomer, inhibits blood vessel formation of IH patient-derived hemangioma stem cells (HemSC) xenografted in mice. HemSC are multipotent cells with the ability to differentiate into endothelial cells, pericytes, and adipocytes. Objectives We investigated how R(+) propranolol affects HemSC adipogenic differentiation and lipid accumulation, in vitro and in a preclinical murine model for IH. Methods We conducted a 10-day adipogenesis assay on 4 IH patient-derived HemSCs. Oil Red O (ORO) staining was used to identify the onset and level of lipid accumulation in HemSC while quantitative real-time polymerase chain reaction was conducted to determine the temporal expression of key factors implicated in adipogenesis. 5-20µM R(+) propranolol treatment was added to HemSC induced to undergo adiogenesis for 4 and 8 days, followed by quantification of lipid-stained areas and transcript levels of key adipogenic factors. We immunostained for lipid droplet-associated protein Perilipin 1 (PLIN1) in HemSC-xenograft sections from mice treated with R(+) propranolol and quantified the area using ImageJ. Results We found that different patient-derived HemSC exhibit a robust and heterogenous adipogenic capacity when induced for adipogenic differentiation in vitro. Consistently across four IH patient-derived HemSC isolates, R(+) propranolol reduced ORO-stained areas and lipoprotein lipase (LPL) transcript levels in HemSC after 4 and 8 days of adipogenic induction. In contrast, R(+) propranolol had no significant inhibitory effect on transcript levels encoding adipogenic transcription factors. In a pre-clinical HemSC xenograft model, PLIN1-positive area was significantly reduced in xenograft sections from mice treated with R(+) propranolol, signifying reduced lipid accumulation. Conclusions Our findings suggest a novel regulatory role for the R(+) enantiomer of propranolol in modulating lipid accumulation in HemSC. This highlights a novel role of R(+) propranolol in the involuting phase of IH and a strategy to reduce fibrofatty residua in IH. What is already known about this topic? Propranolol is the mainstay treatment for infantile hemangioma (IH), the most common tumor of infancy, but its use can be associated with concerning β-blocker side effects. R(+) propranolol, the enantiomer largely devoid of β-blocker activity, was recently shown to inhibit endothelial differentiation of hemangioma-derived stem cells (HemSC) in vitro and reduce blood vessel formation in a HemSC-derived xenograft murine model of IH. What does this study add? R(+) propranolol inhibits lipid accumulation in HemSC in vitro. R(+) propranolol does not affect mRNA transcript levels of key adipogenic transcription factors in differentiating HemSC in vitro. R(+) propranolol reduces lipid accumulation in a pre-clinical xenograft murine model of IH. What is the translational message? The R(+) enantiomer of propranolol could be advantageous in terms of reduction in β-adrenergic side effects and fibrofatty tissue formation in the involuting phase of IH. Less fibrofatty residua might reduce the need for surgical resection. Disfigurement and associated psychosocial impacts might be improved in this young patient cohort.
Open AccessR(+) Propranolol decreases lipid accumulation in hemangioma-derived stem cells
Background Infantile hemangioma (IH) is a benign vascular tumor that undergoes an initial rapid growth phase followed by spontaneous involution. A fibrofatty residuum remains in many tumors and often necessitates resection. We recently discovered that R(+) propranolol, the non-β blocker enantiomer, inhibits blood vessel formation of IH patient-derived hemangioma stem cells (HemSC) xenografted in mice. HemSC are multipotent cells with the ability to differentiate into endothelial cells, pericytes, and adipocytes. Objectives We investigated how R(+) propranolol affects HemSC adipogenic differentiation and lipid accumulation, in vitro and in a preclinical murine model for IH. Methods We conducted a 10-day adipogenesis assay on 4 IH patient-derived HemSCs. Oil Red O (ORO) staining was used to identify the onset and level of lipid accumulation in HemSC while quantitative real-time polymerase chain reaction was conducted to determine the temporal expression of key factors implicated in adipogenesis. 5-20µM R(+) propranolol treatment was added to HemSC induced to undergo adiogenesis for 4 and 8 days, followed by quantification of lipid-stained areas and transcript levels of key adipogenic factors. We immunostained for lipid droplet-associated protein Perilipin 1 (PLIN1) in HemSC-xenograft sections from mice treated with R(+) propranolol and quantified the area using ImageJ. Results We found that different patient-derived HemSC exhibit a robust and heterogenous adipogenic capacity when induced for adipogenic differentiation in vitro. Consistently across four IH patient-derived HemSC isolates, R(+) propranolol reduced ORO-stained areas and lipoprotein lipase (LPL) transcript levels in HemSC after 4 and 8 days of adipogenic induction. In contrast, R(+) propranolol had no significant inhibitory effect on transcript levels encoding adipogenic transcription factors. In a pre-clinical HemSC xenograft model, PLIN1-positive area was significantly reduced in xenograft sections from mice treated with R(+) propranolol, signifying reduced lipid accumulation. Conclusions Our findings suggest a novel regulatory role for the R(+) enantiomer of propranolol in modulating lipid accumulation in HemSC. This highlights a novel role of R(+) propranolol in the involuting phase of IH and a strategy to reduce fibrofatty residua in IH. What is already known about this topic? Propranolol is the mainstay treatment for infantile hemangioma (IH), the most common tumor of infancy, but its use can be associated with concerning β-blocker side effects. R(+) propranolol, the enantiomer largely devoid of β-blocker activity, was recently shown to inhibit endothelial differentiation of hemangioma-derived stem cells (HemSC) in vitro and reduce blood vessel formation in a HemSC-derived xenograft murine model of IH. What does this study add? R(+) propranolol inhibits lipid accumulation in HemSC in vitro. R(+) propranolol does not affect mRNA transcript levels of key adipogenic transcription factors in differentiating HemSC in vitro. R(+) propranolol reduces lipid accumulation in a pre-clinical xenograft murine model of IH. What is the translational message? The R(+) enantiomer of propranolol could be advantageous in terms of reduction in β-adrenergic side effects and fibrofatty tissue formation in the involuting phase of IH. Less fibrofatty residua might reduce the need for surgical resection. Disfigurement and associated psychosocial impacts might be improved in this young patient cohort.